Coenzyme Q10 Aerosol

Abstract

The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.

1 . (canceled) 
     
     
         2 . (canceled) 
     
     
         3 . (canceled) 
     
     
         4 . (canceled) 
     
     
         5 . (canceled) 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . (canceled) 
     
     
         9 . (canceled) 
     
     
         10 . (canceled) 
     
     
         11 . (canceled) 
     
     
         12 . (canceled) 
     
     
         13 . (canceled) 
     
     
         14 . (canceled) 
     
     
         15 . (canceled) 
     
     
         16 . (canceled) 
     
     
         17 . (canceled) 
     
     
         18 . (canceled) 
     
     
         19 . (canceled) 
     
     
         20 . (canceled) 
     
     
         21 . (canceled) 
     
     
         22 . (canceled) 
     
     
         23 . (canceled) 
     
     
         24 . (canceled) 
     
     
         25 . An aerosol formulation comprising coenzyme Q10 having an effective oil phase dispersion size of 1 micron or less, that has been re-dispersed from a solid dry matrix. 
     
     
         26 . The formulation of  claim 25 , wherein the aerosol is in the form of a nanoemulsion. 
     
     
         27 . The formulation of  claim 26  further comprising one or more carriers, one or more oils, one or more surfactants or a combination thereof. 
     
     
         28 . A coenzyme Q10 formulation comprising: a first stage comprising an emulsion containing coenzyme Q10 having an effective oil phase dispersion size of 1 micron or less; a second stage comprising a solid dry matrix formed from a dried state of said first stage emulsion; and a third stage aerosol comprising an emulsion formed from a re-dispersed said second stage solid. 
     
     
         29 . The formulation of  claim 27  wherein a drying technique such as for example, freeze drying, or spray drying. 
     
     
         30 . A method of preparing a coenzyme Q10 formulation, comprising the steps of: preparing a first stage comprising an emulsion containing coenzyme Q10 having an effective oil phase dispersion size of 1 micron or less;
 preparing a second stage comprising a solid dry matrix formed from a dried state of said first stage emulsion; and preparing a third stage aerosol comprising an emulsion formed from a re-dispersed said second stage solid.   
     
     
         31 . The method of  claim 30  wherein said second stage is prepared by freeze drying or spray drying. 
     
     
         32 . A method for making an aerosol formulation containing a desired amount of CoQ10 comprising the steps of:
 dissolving CoQ10 in an oil to create an oil phase;   adding at least one surfactant to said oil phase;   adding water to create an emulsion;   adding at least one tonicity agent to make the emulsion isotonic, said emulsion   containing therein droplets of CoQ10 having a first average size;   freeze drying said emulsion; and   rehydrating said freeze dried emulsion with water to make an isotonic emulsion, upon rehydration said emulsion containing therein droplets of CoQ10 having a second average droplet size that is less than said first average droplet size.   
     
     
         33 . The method of  claim 32  having a mixture ratio of 0.03 g of
 CoQ10 to 0.5 g of oil. 
 
     
     
         34 . The method of  claim 32  having a mixture ratio of 60 g oil, 1 g water, 0.5 g oil, 0.5 g surfactant, and 0.03 g CoQ10. 
     
     
         35 . The method of  claim 32  wherein said second average droplet size is 117 nanometers or less. 
     
     
         36 . The method of  claim 32  wherein said second average droplet size is 64 nanometers or less. 
     
     
         37 . A method of treating a disorder comprising administering to a subject in need of thereof the aerosol formulation of  claim 32 . 
     
     
         38 . The method of  claim 37  wherein disorder is cancer, cardiovascular disease or obesity. 
     
     
         39 . The method of  claim 37  wherein said formulation is administered by aerosolization using a jet, ultrasonic, pressurized or vibrating porous plate nebulizer or other device capable of delivering the formulation to the nasal passages and/or pulmonary airway.